Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes. by Niwa Yuichi et al.
Physiology and Pharmacology
Ranibizumab and Aflibercept: Intraocular
Pharmacokinetics and Their Effects on Aqueous VEGF
Level in Vitrectomized and Nonvitrectomized Macaque
Eyes
Yuichi Niwa,1 Masashi Kakinoki,1 Tomoko Sawada,1 Xiying Wang,1,2 and Masahito Ohji1
1Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan
2Key Laboratory of Harbin Medical University Eye Center, Eye Hospital, First Affiliated Hospital, Harbin Medical University, Harbin,
People’s Republic of China
Correspondence: Yuichi Niwa, De-
partment of Ophthalmology, Shiga




Submitted: May 16, 2015
Accepted: August 28, 2015
Citation: Niwa Y, Kakinoki M, Sawada
T, Wang X, Ohji M. Ranibizumab and
aflibercept: intraocular pharmacoki-
netics and their effects on aqueous
VEGF level in vitrectomized and non-
vitrectomized macaque eyes. Invest
Ophthalmol Vis Sci. 2015;56:6501–
6505. DOI:10.1167/iovs.15-17279
PURPOSE. We evaluated the pharmacokinetics of intravitreally injected ranibizumab and
aflibercept, and their effects on VEGF in the aqueous humor of vitrectomized and
nonvitrectomized macaque eyes.
METHODS. Intravitreal ranibizumab (IVR; 0.5 mg/50 lL) or intravitreal aflibercept (IVA; 2 mg/
50 lL) was injected into the previously vitrectomized right eyes of three macaques and
nonvitrectomized right eyes of three macaques. The left eyes served as controls (non-
vitrectomized, noninjected). Aqueous humor was obtained from both eyes just before
injection and on days 1 and 3, and weeks 1 to 8 after IVR and IVA. The ranibizumab,
aflibercept, and VEGF concentrations were measured using enzyme-linked immunosorbent
assays.
RESULTS. The half-lives in aqueous humor of nonvitrectomized and vitrectomized eyes were,
respectively, 2.3 and 1.4 days for ranibizumab, and 2.2 and 1.5 days for aflibercept.
Concentration of VEGF was decreased below the limit of detection (LOD) by IVR for 3 weeks
in nonvitrectomized eyes and 1 week in vitrectomized eyes, respectively, and by IVA for 6
weeks in nonvitrectomized eyes and 4 weeks in vitrectomized eyes, respectively. In the
untreated control eyes, the ranibizumab and aflibercept concentrations were below the LOD,
and the VEGF aqueous concentrations remained unchanged after IVR and decreased for 3
days after IVA.
CONCLUSIONS. Intravitreally injected ranibizumab and aflibercept have similar half-lives in
aqueous humor and shorter half-lives in vitrectomized eyes. Compared to IVR, IVA suppresses
VEGF level for a longer time period.
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Ranibizumab (Lucentis; Genentech, Inc., South San Francis-co, CA, USA) and aflibercept (Eylea; Regeneron Pharma-
ceuticals, Tarrytown, NY, USA) are VEGF inhibitors used for the
treatment of age-related macular degeneration (AMD), myopic
choroidal neovascularization, macular edema following retinal
vein occlusion, and diabetic macular edema. Ranibizumab is a
recombinant, humanized monoclonal antibody fragment that
neutralizes all biologically active forms of VEGF-A.1 Aflibercept
is a recombinant fusion protein comprised of portions of
human VEGFR1 and VEGFR2 extracellular domains fused to the
Fc portion of human immunoglobulin G1.2 Ranibizumab and
aflibercept are used widely. There are many reports about their
efficiency,3–11 but only a few about their pharmacokinetics. We
previously reported the intraocular pharmacokinetics of
bevacizumab and its effect on aqueous VEGF concentration in
vitrectomized and nonvitrectomized macaque eyes.12,13 Chris-
toforidis et al.14 and Ahn et al.15 reported the intraocular
pharmacokinetics of ranibizumab in vitrectomized and non-
vitrectomized rabbit eyes. Gaudreault et al.16 reported the
pharmacokinetics of ranibizumab in monkey eyes. To our best
knowledge, no one has reported the pharmacokinetics of
aflibercept in monkey eyes. Therefore, we measured concen-
trations of ranibizumab, aflibercept, and VEGF over time in the
aqueous humor of vitrectomized and nonvitrectomized eyes
after the injection of intravitreal ranibizumab (IVR) and
intravitreal aflibercept (IVA) in macaques.
METHODS
All treatments were in accord with principles of the Association
for Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research, and the
animal research protocol was approved by the Animal
Experimentation Committee at Shiga University of Medical
Science. Six male cynomolgus macaques were used in this
study. A procedure consisting of pars plana vitrectomy with
lensectomy was performed in the right eyes of three macaques,
at least 6 months before the experiments. Each macaque was
anesthetized with 5 mg/kg intramuscular ketamine hydrochlo-
ride and 1 mg/kg intramuscular xylazine hydrochloride.
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Povidone iodine was placed on the conjunctiva of each eye.
Using a 29-gauge needle, ranibizumab (0.5 mg/50 lL) was
injected into the vitreous cavity of the right eye of each
macaque. The left eyes received no intravitreal injections and
served as controls. Using a 29-gauge needle, aqueous humor
samples (150 lL) from both eyes were obtained just before
injection and on days 1 and 3, and weeks 1 to 8 after IVR. At
least 6 months after IVR, aflibercept (2 mg/50 lL) was injected
into the vitreous cavity of the right eye, and aqueous humor
samples (150 lL) from both eyes were obtained just before
injection and on days 1 and 3, and weeks 1 to 8 after IVA. The
depth of the anterior chamber remained normal at all times
after the samples were obtained. The samples were stored in a
freezer at 808C until analysis.
Measurement of VEGF
Aqueous VEGF concentrations were measured using an ELISA
(Quantikine Human VEGF Immunoassay; R&D Systems,
Minneapolis, MN, USA). According to the manufacturer’s
instructions, the detection limit of VEGF was 9.0 pg/mL. A
VEGF concentration less than the limit of detection (LOD) was
considered as 0 in the calculation of the mean.
Measurement of Ranibizumab and Aflibercept
Concentrations
Aqueous ranibizumab and aflibercept concentrations were
measured by ELISA. A total of 96 well plates were coated with
recombinant human VEGF165 (R&D Systems) at a concentra-
tion of 1.0 lg/mL overnight at 48C (100 lL/well). After washing
three times with PBS containing 0.05% Tween-20, the wells
were blocked with 3% BSA/PBS overnight at 48C (200 lL/well),
washed five times with PBS containing 0.05% Tween-20, and
stored dry at 48C for later use. Aqueous humor diluted in 0.1%
BSA/PBS (50 lL/well) was added to the plates, which were
incubated overnight at 48C. Ranibizumab and aflibercept were
detected by incubation with horseradish peroxidase-goat anti-
human IgG (HþL) conjugate (1 lg/mL; Invitrogen Corporation,
Carlsbad, CA, USA) for 2 hours at room temperature, five
washes, color development with a 100 lL 3,30,5,50-tetramethyl
benzidine substrate, and addition of 1 M HCl (100 lL) to stop
the reaction. The optical density was measured at 450 nm with
correction at 570 nm. A standard curve was prepared with
ranibizumab and aflibercept concentrations ranging from 7.8
to 4000 pg/mL. The minimal quantifiable concentration of
ranibizumab and aflibercept was 15.6 pg/mL. Because the
sample volumes were small, they were diluted 10 times before
measurement. Therefore, the LODs of ranibizumab and
aflibercept in aqueous humor were 156 pg/mL (0.156 ng/
mL). This sandwich ELISA assay only measured free ranibizu-
mab/aflibercept rather than total concentration of free and
VEGF-bound ranibizumab/aflibercept.
Pharmacokinetic Analysis
The pharmacokinetic properties of ranibizumab and afliber-
cept were determined using a one-compartment model as
described in our previous report on bevacizumab.12,13 This
method assumes that drug clears from the eye monoexponen-
tially. The experimental concentration data of ranibizumab and
aflibercept were fit to the following equation with Standard
Microsoft Excel 2010 software (Microsoft, Redmond, WA,
USA):
CðtÞ ¼ C0expðktÞ;
where C (lg/mL) and C0 (lg/mL) denote concentration at any
time t (in days), and at t ¼ 0, respectively. C0 is the baseline
concentration, and k indicates the elimination rate constant.
The half-life (t1/2) was calculated as 0.693/k.
The areas under the curve (AUC) were estimated by a linear-
trapezoidal method.
Statistical Analysis
All statistical analyses were done using PASW Statistics 18 (SPSS
Japan, Tokyo, Japan).
RESULTS
In the injected nonvitrectomized eyes, mean ranibizumab
concentrations in the aqueous humor peaked at 51,300 ng/mL
(n ¼ 3; range, 45,700–61,500) the day after IVR injection and
fell below the LOD 6 weeks later. The half-life of 0.5 mg IVR in
the aqueous humor was 2.3 days (n¼ 3; range, 2.0–2.4). In the
injected vitrectomized eyes, mean ranibizumab concentrations
in the aqueous humor peaked at 41,800 ng/mL (n ¼ 3; range,
34,200–58,200) the day after IVR and fell below the LOD 4
weeks after IVR. The half-life was 1.4 days (n¼ 3; range, 1.0–
2.0; Fig. 1). Ranibizumab was not detected in the untreated
fellow eyes.
In the injected nonvitrectomized eyes, the mean aflibercept
concentration in the aqueous humor peaked at 74,000 ng/mL
(n ¼ 3; range, 65,300–88,800) the day after IVA injection and
fell below the LOD 6 weeks after IVA injection. The half-life of
2 mg intravitreally injected aflibercept in the aqueous humor
was 2.2 days (n ¼ 3; range, 2.2–2.3). In the injected
vitrectomized eyes, aflibercept concentrations in the aqueous
humor peaked at 68,000 ng/mL (n¼ 3; range, 40,100–97,900)
the day after IVA and fell below the LOD 4 weeks after IVA. The
half-life was 1.5 days (n¼ 3; range, 1.3–1.8; Fig. 2). Aflibercept
was not detected in the untreated fellow eyes.
FIGURE 1. Ranibizumab concentrations in the aqueous humor of
nonvitrectomized eyes and vitrectomized eyes after intravitreal
injection.
FIGURE 2. Aflibercept concentrations in the aqueous humor of
nonvitrectomized eyes and vitrectomized eyes after intravitreal
injection.
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The mean aqueous VEGF concentration of the injected
nonvitrectomized eyes was 99.7 pg/mL (n ¼ 3; range, 63.1–
159.4) before IVR injection. One day after the IVR, the aqueous
VEGF concentrations decreased to less than 9.0 pg/mL (the
LOD) in all injected eyes. The concentration decreased below
the LOD for 3 weeks in nonvitrectomized eyes. The mean
aqueous VEGF concentration of the injected vitrectomized
eyes was 78.1 pg/mL (n ¼ 3; range, 16.5–139.2) before IVR.
One day after IVR, the aqueous VEGF concentrations
decreased to the LOD in all injected eyes and concentration
below the LOD was maintained for 1 week in vitrectomized
eyes (Fig. 3). The mean aqueous VEGF concentration of
noninjected fellow eyes was 93.1 pg/mL (n ¼ 3; range, 14.8–
169.0) before IVR and remained unchanged throughout the
experiment (Fig. 4).
The mean aqueous VEGF concentration of the injected
nonvitrectomized eyes was 82.0 pg/mL (n ¼ 3; range, 53.2–
132.6) before IVA injection, decreased to less than the LOD in
all injected eyes 1 day after IVA, and remained below the LOD
for 6 weeks. The mean aqueous VEGF concentration in
injected vitrectomized eyes was 74.7 pg/mL (n ¼ 3; range,
28.7–110.7) before IVA injection, decreased to less than the
LOD in all injected eyes, and remained below the LOD for 4
weeks (Fig. 5). The mean aqueous VEGF concentration of the
noninjected fellow eyes was 59.5 pg/mL (n ¼ 6; range, 24.5–
110.2) before IVA, decreased significantly to 15.0 pg/mL 1 day
after IVA, and decreased to 22.6 pg/mL 3 days after IVA (Fig. 6).
The Table shows the maximum drug concentration, AUC,
and half-life of ranibizumab and aflibercept in the aqueous
humor of the injected eyes.
No complications, such as uveitis or endophthalmitis,
developed after ranibizumab and aflibercept were injected.
DISCUSSION
In the current study, the half-life of 0.5 mg intravitreally
injected ranibizumab in the aqueous humor was 2.3 days (n¼
3) in nonvitrectomized eyes and 1.4 days (n ¼ 3) in
vitrectomized eyes, and the half-life of 2 mg intravitreally
injected aflibercept in the aqueous humor was 2.2 days (n¼ 3)
in nonvitrectomized eyes and 1.5 days (n¼ 3) in vitrectomized
eyes. Previously, we showed a similar half-life for 1.25 mg
intravitreally injected bevacizumab in the aqueous humor (i.e.,
2.8 days in nonvitrectomized eyes and 1.5 days in vitrectom-
ized eyes).12,13 In previous studies, the aqueous humor half-life
of ranibizumab was 2.54 days in monkey eyes16 and 7.15 days
in human eyes.17 Although to our knowledge no reported
studies have determined the half-life of intravitreal aflibercept
injection in monkey and human eyes, Stewart18 estimated a
half-life for aflibercept of 7.13 days in human eyes. Together
with our current results, the data seem to indicate a similarity
between ranibizumab and aflibercept in intraocular pharma-
cokinetics. However, it is expected that ranibizumab and
aflibercept would be effective for different periods because
their affinities differ.
FIGURE 3. Vascular endothelial growth factor concentrations in the
aqueous humor of nonvitrectomized eyes and vitrectomized eyes after
intravitreal ranibizumab injection.
FIGURE 4. Vascular endothelial growth factor concentrations in the
aqueous humor of noninjected fellow eyes after ranibizumab
intravitreal injection.
FIGURE 5. Vascular endothelial growth factor concentrations in the
aqueous humor of nonvitrectomized eyes and vitrectomized eyes after
intravitreal aflibercept injection.
FIGURE 6. Vascular endothelial growth factor concentrations in the
aqueous humor of noninjected fellow eyes after intravitreal aflibercept
injection.
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In the current study, the half-lives of ranibizumab and
aflibercept in the aqueous humor were shorter in vitrectom-
ized than nonvitrectomized eyes. These results are consistent
with our previous bevacizumab results.12,13 Some studies have
suggested that vitrectomy with lensectomy decreases the half-
life of intravitreal molecules. The vitreous half-life of ampho-
tericin-B was reduced from 9.1 to 1.4 days after vitrectomy and
lensectomy in rabbit eyes,19 5-fluorouracil clearance was
increased two times in aphakic vitrectomized rabbit eyes
compared to phakic vitrectomized eyes,20 and the intravitreal
half-life of bevacizumab in rabbits was decreased from 4.22 to
2.08 days after vitrectomy and lensectomy.14 Thus, vitrectomy
with lensectomy may increase intravitreal drug clearance. On
the other hand, Ahn et al.21 compared the pharmacokinetics of
intravitreal bevacizumab (IVB) in lens-sparing vitrectomized
versus nonvitrectomized control rabbit eyes and reported no
significant differences in IVB pharmacokinetics between them.
They recently reported similar findings in eyes injected with
ranibizumab.15 The significant differences between vitrectom-
ized and nonvitrectomized eyes in the current study may be
due not only to vitrectomy, but also lensectomy.
In the current study, IVR decreased the VEGF concentration
for 1 week in vitrectomized eyes (n ¼ 3) and 3 weeks in
nonvitrectomized eyes (n ¼ 3). Our previously study of
bevacizumab showed IVB decreased VEGF level below the
LOD for 1 week in vitrectomized eyes and 4 weeks in
nonvitrectomized eyes.12,13 Both IVR and IVB maintained
VEGF levels below the LOD for comparable periods. The CATT
Research Group showed that IVB and IVR had equivalent
effects on visual acuity when administered on the same
schedule.22 Our results supported this conclusion.
In the current study, IVA decreased the VEGF concentration
for 4 weeks in the vitrectomized (n ¼ 3) and 6 weeks in the
nonvitrectomized (n¼ 3) eyes. Also, IVA decreased VEGF level
below the LOD for a longer period compared to IVR. The VEGF
concentration fell below the LOD, while the aflibercept
remained detectable. On the other hand, the VEGF concentra-
tion recovered even though a small amount of ranibizumab still
was detectable. Binding of VEGF to aflibercept exceeds that to
bevacizumab and ranibizumab. According to a previous report,
the equilibrium dissociation constant (KD) of the aflibercept–
VEGF–A165 complex is 0.490 pM, while those for ranibizumab
and bevacizumab are 46 and 58 pM, respectively.23 The higher
binding affinity of aflibercept may account for its more
persistent blockade of VEGF.24 Investigation of Efficacy and
Safety in Wet AMD (VIEW) 1 and VIEW 2 studies showed that
bimonthly intravitreal injection of aflibercept after 3 loading
doses was noninferior to monthly injection of ranibizumab.6
Our results supported the need for less frequent dosing with
aflibercept than ranibizumab.
Although the baseline VEGF level seems to be lower in the
IVA study than in the IVR study, the difference was not
statistically significant. We believe that it was simply due to
experimental variability. In the current study, the aqueous
VEGF concentrations in noninjected fellow eyes (n ¼ 6) were
decreased significantly for 3 days after IVA even though no
aflibercept was detectable. In our previous study of bevacizu-
mab, the VEGF concentrations in the aqueous humor of fellow
eyes remained unchanged throughout the experiment, al-
though small amounts of bevacizumab were detectable. Wang
et al.25 reported that serum and plasma VEGF concentrations
are significantly decreased by IVA, but not affected by IVR. Very
small amounts of aflibercept may escape into the systemic
circulation, and because of its strong VEGF binding activity,
suppress VEGF level in fellow eye.
In conclusion, the half-lives of intravitreally injected
ranibizumab and aflibercept in the aqueous humor are similar.
Their aqueous humor half-lives are shorter in vitrectomized
eyes with lensectomy than in eyes without surgery. Compared
to IVR, IVA suppressed VEGF level in injected eyes for a longer
period, and in noninjected fellow eyes for a short time period.
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